Genmab A/S

Company GMAB

Last mentioned: 3d ago

Stories mentioning Genmab A/S 2

Earnings Neutral

Genmab Faces Profit Squeeze as R&D for ADC Pipeline Weighs on 2026 Outlook

Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.

2 sources
Markets Very Bullish

Biotech Volatility and Earnings Pressures Define Mixed Market Session

The equity markets are navigating a complex landscape of 'sell-the-news' reactions and extreme biotech volatility following a series of clinical and financial updates. While Compass Pathways surged on positive trial results, Ocular Therapeutix and Genmab faced significant selling pressure despite reaching key milestones.

9 sources